6533b838fe1ef96bd12a3e1b

RESEARCH PRODUCT

Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

Beata M Labuz-roszakMaciej BanachMichal SkrzypekAdam WindakTomasz TomasikMiroslaw MastejMaciej TomaszewskiDimitri MikhailidisPeter TothAlberico Luigi CatapanoKausik RayGeorge HowardGregory LipFadi J CharcharNaveed SattarBryan WilliamsThomas MacdonaldPeter PensonJacek Jozwiak On Behalf Of The Lipidogram2015 Investigators

subject

Oral anticoagulant drugsmedicine.medical_specialtyRMArticleLifestyle modificationOral antiplatelet drugsInternal medicineIschaemic strokemedicineMyocardial infarctioncardiovascular diseasesSecondary stroke preventionStrokePrimary health careoral anticoagulant drugssecondary stroke preventionbusiness.industryRAtrial fibrillationoral antiplatelet drugsGeneral Medicinemedicine.diseaseR1Coronary heart diseaseprimary health careStroke preventionConcomitantMedicinebusiness

description

Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were associated with antiplatelet treatment (p = 0.047 and p = 0.012, respectively). A history of atrial fibrillation, CHD, and previous myocardial infarction correlated with anticoagulant treatment (p = 0.001, p = 0.011, and p &lt

yearjournalcountryeditionlanguage
2021-10-01
10.3390/jcm10194472